Roche remain committed after discontinuing CREAD programme

30 January 2019 – Pharmaceutical company Roche has announced the discontinuation of their CREAD programme. This was following the finding of two Phase III trials that crenezumab, a possible new drug treatment for Alzheimer’s disease, was not expected to meet its efficacy targets. The Alzheimer’s Prevention Initiative (API) will continue to investigate crenezumab in a pivotal trial to prevent Alzheimer’s disease in healthy people with familial Alzheimer’s disease. Crenezumab was discovered by Swiss biotechnology company AC Immune SA and developed by Roche.

Alzheimer’s disease is the most common form of dementia, the collective term for a range of degenerative neurological conditions that affect memory, thinking, behaviour and emotion. There is no cure for dementia and has been no new treatment for the symptoms of dementia since 2002.

ADI is assured that Roche is still committed to the field and it continues with other trials, including the development of gantenerumab and the anti-tau molecule RG6100 (which is also being developed through a collaboration with AC Immune), as well as diagnostic solutions.

Paola Barbarino, CEO of ADI, said:

“While we are of course frustrated by the news on this particular trial, we are reassured by the ongoing commitment and innovation of our colleagues at Roche and AC Immune to find treatments that will improve the lives of people with dementia and their families across the world. We must take stock of what was learned from the trial and continue to support those affected by dementia globally.”

More investment is needed to support research on dementia across all key areas: basic science, care improvements, prevention and risk reduction, drug development and public health. Read more in the World Alzheimer Report 2018 and join our Global webinars on research participation.

Where next?